Anti-human CRTH2 Antibody Specific Epitope Binding

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current anti-human CRTH2 antibodies lack desired activity such as specific binding to human CRTH2 and efficacy on human CRTH2 ligand-dependent activity, necessitating the development of an antibody that recognizes and binds to specific epitopes on human CRTH2.

Innovation Solution

An antibody or antibody fragment that specifically recognizes and binds to specific amino acid residues on human CRTH2, including glycine and aspartic acid, with characteristics such as high reactivity to CRTH2-expressing cells and absence of agonist or neutralizing activity, even in the presence of ligands, is developed.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing anti-human CRTH2 antibodies are used, then general binding to CRTH2 is achieved, but specific binding activity and therapeutic efficacy are insufficient

Engineering Contradiction:

Improvespecific binding activityVSAvoidtherapeutic efficacy

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by directing the antibody to bind specifically to particular amino acid residues (glycine and aspartic acid) within the CRTH2 receptor structure. This localized binding to specific epitopes enhances both binding specificity and therapeutic efficacy, resolving the contradiction between general binding and targeted therapeutic action.

Inventive Principle:

Principle #3Local quality

2Reliability

If the antibody binds to CRTH2 with high reactivity, then therapeutic effects are enhanced, but agonist or neutralizing activity may be inadvertently activated

Engineering Contradiction:

Improvetherapeutic effectVSAvoidagonist or neutralizing activity

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The antibody is designed to bind to specific local regions (glycine and aspartic acid residues) of the CRTH2 receptor that do not trigger agonist or neutralizing activity. This localized binding approach allows high reactivity and therapeutic effect while avoiding harmful side effects.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent converts the potential harm of unintended agonist or neutralizing activity into benefit by carefully selecting binding epitopes that provide therapeutic effects without activating harmful pathways. The specific binding to glycine and aspartic acid residues ensures therapeutic efficacy while avoiding harmful side effects.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS10100120B2Antibody which specifically binds to human CRTH2

Publication Date: 2018.10.16 KYOWA HAKKO KIRIN CO LTD

AI summary

There is provided an anti-human CRTH2 antibody which has desired activity by recognizing and binding to a specific human CRTH2; the antibody fragment; DNA which encodes the amino acid sequence of the antibody; a vector which comprises the DNA; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of Th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.